TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA

Joana Torres  ¹     Gareth Parkes  ^{2, 3}     Ken Takeuchi  ⁴     Si Xuan  ⁵     James Crooks  ⁵     Justin Klaff  ⁵     Yuri Sanchez Gonzalez  ⁵     Silvio Danese  ^6    
1 Hospital Beatriz Ângelo, Lisbon, Portugal
² Barts and the London School of Medicine and Dentistry, London, United Kingdom
³ Barts Health NHS Trust, London, United Kingdom
⁴ IBD Center, Tsujinaka Hospital Kashiwanoha, Kashiwa, Japan
⁵ AbbVie, Inc., North Chicago, United States
⁶ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy

Topic
IBD

Session
Hit the road JAK: Part 2

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)